tirzepatide 0.5 ml Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Zepbound Tirzepatide Injection 5 mg/0.5

Anti-obesity (AOM) GLP-1 prescriptions skew very heavily to the Commercial channel (81%), while anti-diabetic GLP-1s show a more balanced distribution: a smaller proportion of Commercial claims than AOM GLP-1s but a notably larger proportion than SGLT2s

However, persistently abnormal colours may signal underlying health problems

155 The multi-nutrient tablet provided: In an uncontrolled clinical trial that included 31 participants with one-sided tinnitus, 18 weeks of treatment with a multi-nutrient supplement, providing glycerophosphorylcholine (55 mg/day), glycerophosphorylethanolamine (45 mg/day), beta-carotene (6,000 mcg RAE/day), vitamin C (180 mg/day), and vitamin E (10 mg/day), led to reductions in tinnitus loudness and discomfort

View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings